Skip to main content

Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)

HHS-NIH11 Posted PAR-25-101

Description

The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is sparse or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking.

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Funding Details
Award Floor
Not specified
Award Ceiling
$150,000.00
Total Estimated Funding
$150,000.00
Expected Awards
Not specified
Key Dates
Posted
December 30, 2024
Closes
August 11, 2027 529d
Archive Date
September 16, 2027
Agency Information
Agency Name
HHS-NIH11
Agency Code
HHS-NIH11
Funding Instrument
Other